Companies / Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc.
ALPNNVLSCIK 1626199
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Dec 28, 2023 | Thompson Peter A. Director | Sell Open-market sale | Common Stock | $21.90M | -1.2M -34.49% | 2,270,930 | high |
| Dec 28, 2023 | Orbimed Advisors LLC Director | Sell Open-market sale | Common Stock | $21.90M | -1.2M -34.49% | 2,270,930 | high |
| Jan 18, 2024 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Exercise In-the-money exercise | Common Stock | $15.73M | +1.2M +23.09% | 6,582,380 | low |
| Jan 18, 2024 | Cui Xiangmin Director | Exercise In-the-money exercise | Common Stock | $15.73M | +1.2M +23.09% | 6,582,380 | low |
| Sep 17, 2021 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Buy Open-market buy | Common Stock | $14.50M | +1.5M +48.73% | 4,708,288 | high |
| Sep 17, 2021 | Cui Xiangmin Director | Buy Open-market buy | Common Stock | $14.50M | +1.5M +48.73% | 4,708,288 | high |
| Sep 23, 2022 | Cui Xiangmin Director | Grant Grant or award | Common Stock | $10.00M | +1.4M | 1,360,544 | low |
| Sep 23, 2022 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Grant Grant or award | Common Stock | $10.00M | +1.4M | 1,360,544 | low |